51st Annual Southeastern Wisconsin Cancer Conference: Targeting Advanced Lung Cancer

Milwaukee, WI US
March 16, 2019

The treatment of advanced stage lung cancer continues to evolve with a greater emphasis and targeted and immune therapies.  Our goal is to educate providers on how these treatments work, when they are appropriate, what are the side effects and how are the side effects managed.  Lastly we will include a lecture of the management and treatment of oligometastatic disease. 

 

Our intent is to provide the audience members with an overview of the current practice in the smoking cessation and tobacco control. Lung cancer staging, use of molecular markers, treatment of advanced lung cancer, and the identification and management of treatment side effects.  

 

This meeting is being supported by an unrestricted educational grant:  Takeda Pharmaceuticals
 
 
 
 

Target Audience

  • Physicians
  • Nurses
  • Pharmacists
  • Pharmacy Technicians
  • Allied Health Professionals

Learning Objectives

At the conclusion of this activity, I will be able to:

  • Review current smoking interventions  (counseling, pharmacotherapeutics, NCCN guidelines)
  • Describe updates in TNM (AJCC )  staging  for advanced lung cancer.
  • Discuss advancements in molecular testing and diagnosis in the therapeutic management  of advanced lung cancer
  • Describe and recognize adverse events and immune related side effects from treatment.
  • Discuss diagnosis and treatment options for oliogmetastic disease
Additional information

CME Coordinator Contact Information

Name: 
Mary Kissinger
Phone Number: 
+1 (414) 649-7250
Course summary
Available credit: 
  • 3.25 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 3.25 Hours of Participation
    Hours of Participation credit.
Course opens: 
02/18/2019
Course expires: 
05/15/2019
Event starts: 
03/16/2019 - 7:00am
Event ends: 
03/16/2019 - 1:00pm
Cost:
$0.00
Italian Community Center
631 E. Chicago Street
Milwaukee, WI 53202
United States
Italian Community Center
631 E. Chicago Street
Milwaukee, WI 53202-5916
414-223-2180

 

 

 

Program Planning Committee:
Paul Ritch, MD - President
Deanna Birling MSN AOCNP - Vice President
Gerald Kallas, MD - Treasurer
Mary Kissinger, BS, CTR - Secretary
Charles Bomzer, MD
Joseph Bovi, MD
Beth Brunner, ACS
B.J. Gruling, RPh
Julie Jensen, RN, MSN, C-ANP
Thomas Jensen, MD
Kirk Ludwig, MD
Carolyn Oxencis, PharmD, BCPS, BCOP Laura Raftery, MD
Carrie Riccobono, MSN, RN, ACNSBC, OCN
Johnathan Thompson, MD

 

 

 

Presenters:
Douglas Jorenby, PhD; University of Wisconsin
Grace Dy, MD; Roswell Park
Corey Langer, MD; University of Pennsylvania
Alex Adjei, MD, PhD; Mayo Clinic
Elizabeth Gore, MD; Medical College of Wisconsin
 

 

All persons in control of content have NO relevant financial relationships to disclosure except the following:

 

NameCompanyRole
Charles Bomzer, MDPfizer, Merck, Exact SciencesStock
Corey Langer, MD

Bristol-Myers Squibb Company; ImClone Systems Incorporated;  Pfizer Inc; Eli Lilly and Company; AstraZeneca Pharmaceuticals LP; Merck; Novartis Pharmaceuticals Corporation; Genentech, Inc.; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Celgene Oncology; Abbott Laboratories; Biodesix; Clariant; CarisDx; ARIAD Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Synta Pharmaceuticals Corp; Clovis

 

Amgen, Synta, Peregrine, SWOG, Incyte, VA, Lilly

 

Scientific Advisor

 

 

 

DSMC Member

 

 
In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships.  These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
 
 
 
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and Southeastern Wisconsin Cancer Conference. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
 
AMA PRA Designation Statement 
The Medical College of Wisconsin designates this live activity a maximum of 3.25 AMA PRA Category 1 Credit(s)™ .  Physicians should claim only the credit commensurate with the extent of their participation in the activity

 

Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 3.25 hours of participation for continuing education for allied health professionals

Available Credit

  • 3.25 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 3.25 Hours of Participation
    Hours of Participation credit.

Accreditation Period

Course opens: 
02/18/2019
Course expires: 
05/15/2019

Price

Cost:
$0.00
Please login or register to take this course.

No registration fee